6-Dec-2025 ASH 2025: New MD Anderson-developed antibody boosts immune response against blood cancers and solid cancers University of Texas M. D. Anderson Cancer Center Reports and Proceedings
6-Dec-2025 ASH 2025: CAR T cell therapy shows promising Phase II trial results in multiple myeloma University of Texas M. D. Anderson Cancer Center Reports and Proceedings
6-Dec-2025 ASH 2025: Antibody therapy eradicates traces of multiple myeloma in preliminary trial University of Miami Miller School of Medicine Reports and Proceedings
6-Dec-2025 ASH 2025: AI uncovers how DNA architecture failures trigger blood cancer University of Miami Miller School of Medicine Reports and Proceedings
6-Dec-2025 Protective regimen allows successful stem cell transplant even without close genetic match between donor and recipient American Society of Hematology Reports and Proceedings
6-Dec-2025 Continuous and fixed-duration treatments result in similar outcomes for CLL American Society of Hematology Reports and Proceedings
6-Dec-2025 Measurable residual disease shows strong potential as an early indicator of survival in patients with acute myeloid leukemia American Society of Hematology Reports and Proceedings
6-Dec-2025 Chemotherapy and radiation are comparable as pre-transplant conditioning for patients with b-acute lymphoblastic leukemia who have no measurable residual disease American Society of Hematology Reports and Proceedings
6-Dec-2025 ASH 2025: New study shows that patients can safely receive stem cell transplants from mismatched, unrelated donors University of Miami Miller School of Medicine Reports and Proceedings
6-Dec-2025 Roughly one-third of families with children being treated for leukemia struggle to pay living expenses American Society of Hematology Reports and Proceedings